In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

NitroMed plans reverse merger with Archemix; terminated

Executive Summary

Closely held Archemix (aptamer therapeutics for rare hematological diseases) has decided to go public through a reverse merger with struggling cardiovascular drug company NitroMed. Archemix had cancelled an IPO earlier this year.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Full Acquisition
    • Reverse Acquisition
    • Payment Includes Stock
    • Includes Contract
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register